Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 65

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 65
---
 contracts with suppliers, licensors and other business partners which may require Clearwater or Enfusion, as applicable, to obtain consent from these other parties in connection with the Transactions, or which may otherwise contain limitations applicable to such contracts following the 37

Transactions. If these consents cannot be obtained, the combined company may suffer a loss of potential future revenue, incur costs and lose rights that may be material to the combined
company’s business. In addition, third parties with whom Clearwater or Enfusion currently have relationships may terminate or otherwise reduce the scope of their relationship with either party in anticipation of the Transactions. Any such
disruptions could limit the combined company’s ability to achieve the anticipated benefits of the Transactions. The adverse effect of any such disruptions could also be exacerbated by a delay in the completion of the Transactions or by a
termination of the Merger Agreement.

The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company’s business, financial position, results of operations and cash flows.

The combined company may be exposed to
increased litigation from stockholders, customers, suppliers and other third parties due to the combination of Clearwater’s and Enfusion’s businesses following the Transactions. Such litigation may have an adverse impact on the combined
company’s business, financial position, results of operations and cash flows, or may cause disruptions to the combined company’s operations.

The financial forecasts are based on various assumptions that may not be realized.

The unaudited prospective financial information set forth in the forecasts included under the section titled “The
Transactions—Certain Financial Projections Utilized by the Special Committee and the Enfusion Board” was prepared solely for internal use and is subjective in many respects. Enfusion’s prospective financial information was based
solely upon assumptions of, and information available to, Enfusion’s management when prepared. These estimates and assumptions are subject to uncertainties, many of which are beyond Enfusion’s control and may not be realized. Many factors
mentioned in this Proxy Statement/Prospectus, including the risks outlined in this “Risk Factors” section and the events or circumstances described in the section titled “Cautionary Statement Regarding Forward-Looking Statements”
will be important in determining the combined company’s future results. As a result of these contingencies, actual future results may vary materially from Clearwater’s and Enfusion’s estimates. In view of these uncertainties, the
inclusion of prospective financial information in this Proxy Statement/Prospectus is not and should not be viewed as a representation